مقایسهٔ روشها
روشهای انتخابی خود را کنار هم مرور کنید؛ ردیفهای متفاوت برجسته شدهاند.
| فهرست سریع علائم افسردگی (QIDS)× | برداشت کلی بیمار از تغییر (PGIC)× | |
|---|---|---|
| حوزه | روانشناسی بالینی | روانشناسی بالینی |
| خانواده | Process / pipeline | Process / pipeline |
| سال پیدایش≠ | 2003 | 1976 |
| پدیدآور≠ | A. John Rush | William Guy |
| نوع≠ | Self-report or clinician-administered questionnaire | Self-report single-item rating |
| منبع بنیادین≠ | Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., & Ninan, P. T. (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583. DOI ↗ | Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare. link ↗ |
| نامهای دیگر≠ | QIDS, Quick Inventory of Depressive Symptomatology-Self Report, QIDS-SR | PGIC, Patient Global Impression of Change Scale |
| مرتبط | 4 | 4 |
| خلاصه≠ | The Quick Inventory of Depressive Symptomatology is a 16-item assessment designed by A. John Rush and colleagues to efficiently measure the severity of depressive symptoms in adults. Published in Biological Psychiatry in 2003, the QIDS exists in both self-report (QIDS-SR) and clinician-rated (QIDS-C) versions. It was developed as a brief alternative to the longer Inventory of Depressive Symptomatology (IDS, 30 items) while maintaining comprehensive coverage of DSM-IV depressive symptoms. The QIDS has become a standard outcome measure in treatment research, particularly in large comparative effectiveness trials. | The Patient Global Impression of Change is a single-item, seven-point rating scale asking patients to report their overall impression of change since treatment initiation. Originally published by William Guy in the ECDEU Assessment Manual in 1976, the PGIC has become a standard co-primary endpoint in clinical trials assessing treatment efficacy. The scale is endorsed by the FDA as a patient-reported outcome measure for demonstrating clinical benefit. Despite its simplicity, the PGIC captures patients' holistic perception of improvement—integrating symptom reduction, functional recovery, and subjective well-being. |
| ScholarGateمجموعهداده ↗ |
|
|